Engineering topics

Bagian, James P.

Publications and source records attributed to Bagian, James P..

10 records

NASA NTRS1993

Reach performance while wearing the Space Shuttle launch and entry suit during exposure to launch accelerations

Crewmen aboard the Space Shuttle are subjected to accelerations during ascent (the powered flight phase of launch) which range up to +3 G(sub x). Despite having 33 missions and nine years experience, not to mention all the time spent in development prior to the first flight, no truly quantitative reach study wearing actual crew equipment, using actual Shuttle seats and restraints has ever been done. What little information exists on reach performance while under acceleration has been derived primarily from subjective comments gathered retrospectively from Shuttle flight crews during their post mission debrief. This lack of reach performance data has resulted in uncertainty regarding emergency procedures that can realistically be performed during and actual Shuttle ascent versus what is practiced in the ground-fixed and motion-based Shuttle Simulators. With the introduction on STS-26 of the current Shuttle escape system, the question of reach performance under launch accelerations was once again raised. The escape system's requirement that each crewman wear a Launch/Entry Suit (LES), parachute harness, and parachute were all anticipated to contribute to a further degradation of reach performance during Shuttle ascent accelerations. In order to answer the reach performance question in a quantitative way, a photogrammetric method was chosen so that the actual reach values and associated envelopes could be captured. This would allow quantitative assessment of potential task performance impact and identify areas where changes to our Shuttle ascent emergency procedures might be required. Also, such a set of reach values would be valid for any similar acceleration profile using the same crew equipment. Potential Space Station applications of this data include predicting reach performance during Assured Crew Return Vehicle (ACRV) operations.

Bagian, James P.↗

NASA NTRS1993

Treatment efficacy of intramuscular promethazine for Space Motion Sickness

Intramuscular promethazine and its efficacy in the treatment of Space Motion Sickness (SMS) were evaluated using standardized questions administered during postflight debriefings to crewmembers immediately after their first Shuttle flight. The comparison showed that 25 percent of crewmembers treated with IM promethazine were 'sick' on flight day 2, compared to 50 percent of crewmembers who did not receive promethazine, 90 percent reported immediate symptom relief as well. Untreated crewmembers typically have slow symptom resolution over 72-96 h, and those treated with oral scopolamine/dextroamphetamine show delayed symptom development. This study suggests that intramuscular promethazine is an effective treatment for SMS and merits continued use and further controlled investigations.

Davis, Jeffrey R.↗

NASA NTRS1993

Promethazine and its use as a treatment for space motion sickness

Until Mar. 1989, no effective treatment--either prophylactic or symptomatic--for space motion sickness (SMS) had been discovered. Since Mar. 1989, intramuscular (IM) promethazine (PMZ) has been used in the treatment of SMS with extremely favorably results reported by the crew. A retrospective study was undertaken to quantify the efficacy of IM PMZ since its institution and the incidence of its major anticipated side-effect drowsiness and sedation. The results from a standardized crew medical debriefing conducted immediately after landing and follow-up interviews with the crews were used in establishing the efficacy and incidence of side effects from treatment. Only crews from the first 44 Shuttle flights on their first mission were considered. For a total of 132 crewmembers, 96 exhibited symptoms of SMS; and, of these, 20 were treated with IM PMZ. Ninety percent of those receiving IM PMZ 25-50mg received nearly immediate (less than 2 hours) relief of symptoms and 75 percent required no further treatment through the first 2 days of spaceflight. Those not receiving this treatment did not have any near-term resolution of their symptoms, and 50 percent were still ill through the second day of flight. This represents a significant difference at the p = 0.46 level. In stark contrast to the 60 percent to 73 percent incidence of sedation or drowsiness reported in individuals treated with PMZ in terrestrial environment at the doses used here, less than 5 percent reported these symptoms during spaceflight. IM PMZ is an effective therapy for SMS and is associated with minimal incidence of sedation or drowsiness. This combination of efficacy that is absent of significant side effects represents a substantial improvement in the operational situation of crewmembers afflicted with SMS. Studies to understand the mechanisms underlying these observations will be undertaken in the future.

Bagian, James P.↗

NASA NTRS1993

Cerebral blood velocity and other cardiovascular responses to 2 days of head-down tilt

Spaceflight induces a cephalad redistribution of fluid volume and blood flow within the human body, and space motion sickness, which is a problem during the first few days of space flight, could be related to these changes in fluid status and in blood flow of the cerebrum and vestibular system. To evaluate possible changes in cerebral blood flow during simulated weightlessness, we measured blood velocity in the middle cerebral artery (MCA) along with retinal vascular diameters, intraocular pressure, impedance cardiography, and sphygmomanometry on nine men (26.2 +/- 6.6 yr) morning and evening for 2 days during continuous 10 deg head-down tilt (HDT). When subjects went from seated to head-down bed rest, their heart rate and retinal diameters decreased, and intraocular pressures increased. After 48 h of HDT, blood flow velocity in the MCA was decreased and thoracic impedance was increased, indicating less fluid in the thorax. Percent changes in blood flow velocities in the MCA after 48 h of HDT were inversely correlated with percent changes in retinal vascular diameters. Blood flow velocities in the MCA were inversely correlated (intersubject) with arterial pressures and retinal vascular diameters. Heart rate, stroke volume, cardiac output, systolic arterial pressure, and at times pulse pressure and blood flow velocities in the MCA were greater in the evening. Total peripheral resistance was higher in the morning. Although cerebral blood velocity is reduced after subjects are head down for 2 days, the inverse relationship with retinal vessel diameters, which have control analogous to that of cerebral vessels, indicates cerebral blood flow is not reduced.

Frey, Mary A. B.↗

NASA NTRS1992

Comparison of current Shuttle and pre-Challenger flight suit reach capability during launch accelerations

The Challenger accident prompted the creation of a crew escape system which replaced the former Launch Entry Helmet (LEH) ensemble with the current Launch Entry Suit (LES). However, questions were raised regarding the impact of this change on crew reach capability. This study addressed the question of reach capability and its effects on realistic ground-based training for Space Shuttle missions. Eleven subjects performed reach sweeps in both the LEH and LES suits during 1 and 3 Gx acceleration trials in the Brooks AFB centrifuge. These reach sweeps were recorded on videotape and subsequently analyzed using a 3D motion analysis system. The ANOVA procedure of the Statistical Analysis System program was used to evaluate differences in forward and overhead reach. The results showed that the LES provided less reach capability than its predecessor, the LEH. This study also demonstrated that, since there was no substantial difference between 1 and 3 Gx reach sweeps in the LES, realistic Shuttle launch training may be accomplished in ground based simulators.

Bagian, James P.↗

NASA NTRS1991

First intramuscular administration in the U.S. space program

In the past, the only kind of medicines used for symptomatic treatment of space motion sickness (SMS) in space had been oral, transdermal, or suppositories. This paper describes the effect of the first intramuscular (IM) administration of Phenergan (50-mg in single dose) on SMS in one subject who exhibited grade-3 symptoms and signs which persisted unabated throughout the first and the second flight days aboard the Space Shuttle. Thirty minutes after the injection, the subject had completely recovered. His symptoms were gone, his appetite was back, and he had no recurrences for the remainder of the flight. Since that experiment, intramuscular injections have been given nine more times on subsequent flights, with similar results.

Bagian, James P.↗

NASA NTRS1991

Cerebral blood flow - Comparison of ground-based and spaceflight data and correlation with space adaptation syndrome

The relationship between the cerebral blood flow velocity and the space adaptation syndrome (SAS), which includes symptoms of motion sickness, stuffy head, and/or headaches, was investigated by measuring (using a transcranial Doppler device) differences between the preflight and the inflight cerebral blood flow velocity in crew members who were motion sick and in those who were not sick during a flight aboard KC-135. It was found that the cerebral artery bloodflow inflight did not differ significantly from that recorded preflight, nor did the severity of SAS symptoms correlate directly with the cerebral blood flow.

Bagian, James P.↗

NASA NTRS1990

Effectiveness of the Space Shuttle anti-exposure system in a cold water environment

The purpose of this study was to evaluate the NASA Space Shuttle launch entry suit (LES) and raft for 24 h of protection against cold water immersion. Two configurations, the LES and the LES with raft (LES/r) were evaluated for antiexposure protection. Conditions were selected to simulate worst-case water and air temperatures along projected Space Shuttle ground tracks; i.e., water temperatures = 4.4 C, air temperature = 5.6 C, 1-foot waves (chop), and constant spray. Four males 31-44 years of age and one 32-year-old female were studied once in each configuration. Trials with and without a raft were scheduled for up to 24 and 6 h, respectively. Mean LES trial durations were 150 + or - 9 min and final rectal temperature (FRT) = 36.5 + or - 0.3 C. Mean LES/r trial durations were 398 + or - 126 min and FRT = 35.6 + or - 0.4 C. LES and LES/r trials were terminated for reaching FRT = 35.0 C or subject-requested termination due to discomfort. The longest LES and LES/r trials were terminated due to subject discomfort. Although not achieving the desired durations, the LES and LES/r did prove capable of protecting individuals, respectively, for up to 3 and 13.5 h. Since the longest runs were terminated due to subjective tolerance, actual survival times greater than 3 and 13.5 h could be expected.

Bagian, James P.↗

NASA NTRS1990

Reach performance while wearing the Space Shuttle launch and entry suit during exposure to launch accelerations

A crew of four veteran astronaut/pilots were subjected to sustained linear accelerations of up to 3G(x) in order to quantify crew reach performance while wearing the currently used Launch and Entry Suit (LES). Photogrammetric techniques were used to quantify magnitudes of reach in any direction while subjects rode a centrifuge. Subjects exhibited small changes of reach capability in the +x (forward) direction which ranged from an improvement of 2.04 cm to a decrease of 14.4 cm while reach performance in the +z (overhead) direction was improved in three of four subjects, indicating that any task which could be accomplished under exposure to 1G(x) could definitely be done at 3G(x). The data from this experiment demonstrated that Shuttle crews in training can expect to maintain all of the overhead reach capability evident in good simulator runs and suffer only moderate degradation in the forward reach performance during the launch phase of an actual Shuttle mission.

Bagian, James P.↗

NASA NTRS1990

Heart rate and pulmonary function while wearing the launch-entry crew escape suit (LES) during + Gx acceleration and simulated Shuttle launch

Space shuttle crewmembers have been equipped with a launch-entry crew escape system (LES) since the Challenger accident in 1986. Some crewmembers, wearing the new pressure suit, have reported breathing difficulties and increased effort to achieve the desired range of motion. This study was conducted to quantify the reported increased physical workloads and breathing difficulty associated with wearing the LES. Both veteran astronauts and centrifuge panel members were exposed to various + Gx profiles (including simulated shuttle launch) + Gx on the USAF School of Aerospace Medicine (USAFSAM) human-use centrifuge. Maximum heart rate data showed no increased workload associated with arm and head movement in the LES when compared to the flight suit/helmet ensemble (LEH). However, the LES did impose a significant increase in breathing difficulty beginning at +2.5 Gx which was demonstrated by a decrease in forced vital capacity and subjected questionnaries.

Krutz, Robert W., Jr.↗